Osteoporosis International

, Volume 4, Issue 6, pp 368–381 | Cite as

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report

  • J. A. Kanis
  • J. A. Kanis
Who Study Document


The criteria required for an effective screening strategy for osteoporosis are largely met in Caucasian women. The disease is common and readily diagnosed by the measurement of bone mineral with single- or dual-energy absorptiometry. Such measurements have high specificity but lower sensitivity, so that the value of the technique is greater for those identified as being at higher risk. Against this background there is little evidence that osteoporosis can usefully be tackled by a public health policy to influence risk factors such as smoking, exercise and nutrition. This suggests that it is appropriate to consider targetting of treatment with agents affecting bone metabolism to susceptible individuals. Since the main benefits of the use of hormone replacement therapy (HRT) are probably on cardiovascular morbidity, the major role for selective screening is to direct non-HRT interventions. An appropriate time to consider screening and intervention is at the menopause, but screening at later ages is also worthy of consideration. Since the cost of screening is low and that of bone-active drugs is high, the selective use of screening techniques will improve the cost-benefit ratio of intervention.


Bone mineral measurement Fractures Osteoporosis Screening 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Grisso JA, Baum CR, Turner BJ. What do physicians in practice do to prevent osteoporosis? J Bone Miner Res 1990;5:213–9.Google Scholar
  2. 2.
    Wilkes HC, Meade TW. Hormone replacement therapy in general practice: a survey of doctors in the MRC's general practice research framework. BMJ 1991;302:1317–20.Google Scholar
  3. 3.
    Griffin J, Robinson R. Hormone replacement for osteoporosis. Lancet 1990;335:1163.Google Scholar
  4. 4.
    Peck WA, Barrett-Connor E, Buckwalter JA, et al. Osteoporosis: NIH Consensus Development Conference statement. JAMA 1984;252:799–802.Google Scholar
  5. 5.
    Anonymous. Consensus development conference: prophylaxis and treatment of osteoporosis. BMJ 1989;295:914–17.Google Scholar
  6. 6.
    Anonymous. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med 1991;90:107–10.Google Scholar
  7. 7.
    Anonymous. Consensu development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646–50.Google Scholar
  8. 8.
    Law MR, Wald NJ, Meade TW. Strategies for prevention of osteoporosis and hip fracture. BMJ 1991;303:453–9.Google Scholar
  9. 9.
    Pitt FA, Lloyd-Jones M, Brazier JE, McGrother CW, Kanis JA, Wallace WA, Jones K. The costs and benefits of screening and preventing postmenopausal osteoporosis in the Trent Region. Report of the Trent Osteoporosis Working Group 1990.Google Scholar
  10. 10.
    Cooper C, Shah S, Hand DJ, Adams J. Compston J, Davie M, Woolf A. Screening for vertebral osteoporosis using individual risk factors. Osteoporosis Int 1991;2:48–53.Google Scholar
  11. 11.
    Hoffenberg R, James OFW, Brocklehurst JC, Green ID, Hor-rocks P, Kanis JA, et al. Fractured neck of femur: prevention and management. J R Coll Physicians Lond 1989;23:8–12.Google Scholar
  12. 12.
    Freemantle N. Screening for osteoporosis to prevent fractures. In: Effective health care no. 1. School of Public Health, Leeds, 1992.Google Scholar
  13. 13.
    Sackett DL, Holland WW. Controversy in the detection of disease. Lancet 1975;2:357–9.Google Scholar
  14. 14.
    World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series. Geneva: WHO, 1994.Google Scholar
  15. 15.
    Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res, in press, 1994.Google Scholar
  16. 16.
    Seeley DG, Browner WS, Nevitt MC, Genant HK, Scott JC, Cummings SR. Which fractures are associated with low appendicular bone mass in elderly women? Ann Intern Med 1991;115:837–42.Google Scholar
  17. 17.
    Melton LJ. Epidemiology of fractures. In: Riggs BL, Melton LJ III, editors. Osteoporosis: etiology, diagnosis, and management. New York: Raven Press, 1988:133–54.Google Scholar
  18. 18.
    Johnell O, Gullberg B, Allander E, Kanis JA. The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporosis Int 1992;2:298–302.Google Scholar
  19. 19.
    Winner SJ, Morgan CA, Evans JG. Perimenopausal risk of falling and incidence of distal forearm fracture. BMJ 1989;298:1486–8.Google Scholar
  20. 20.
    Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL. How many women have osteoporosis? J Bone Miner Res 1992;7:1005–10.Google Scholar
  21. 21.
    Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985;7:178–208.Google Scholar
  22. 22.
    Lauritzen JB, Schwarz P, Lund B, McNair P, Transbol I. Changing incidence and lifetime risk of common osteoporosis related fractures: Hvidovre Osteoporosis Study. Osteoporosis Int 1993;3:127–32.Google Scholar
  23. 23.
    Versluysen M. How elderly patients with femoral fracture develop pressure sores in hospital. BMJ 1986;292:1311–3.Google Scholar
  24. 24.
    Miller CW. Survival and ambulation following hip fracture. J Bone Joint Surg [Am] 1978;60:930–4.Google Scholar
  25. 25.
    Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med 1991;151:2026–32.Google Scholar
  26. 26.
    Phillips S, Fox N, Jacobs J, Wright WE. The direct medical costs of osteoporosis for American women aged 45 and older, 1986. Bone 1988;9:271–9.Google Scholar
  27. 27.
    Nydegger V, Rizzoli R, Rapin C-H, Vasey H, Bonjour J-P. Epidemiology of fractures of the proximal femur in Geneva: incidence, clinical and social aspects. Osteoporosis Int 1991;2:42–7.Google Scholar
  28. 28.
    de Bruijn HP. The Colles' fracture: review of literature. Acta Orthop Scand 1987;58 (Suppl 223):7–25.Google Scholar
  29. 29.
    Wadsworth TG. Colles' fracture: failure in management may cause permanent disability. BMJ 1990;301:192–4.Google Scholar
  30. 30.
    Atkins RM, Duckworth T, Kanis JA. The features of algodystrophy following Colles' fracture. J Bone Joint Surg [BR] 1990;72:105–10.Google Scholar
  31. 31.
    Melton LJ, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL. Prevalence and incidence of vertebral deformities. Osteoporosis Int 1993;3:113–9.Google Scholar
  32. 32.
    Ettinger B, Black DM, Nevitt MC, Rundle AC, Cauley JA, Cummings SR, Genant HK and the Study of Osteoporotic Fractures Research Group. Contribution of vertebral deformities to chronic back pain and disability. J Bone Miner Res 1992;7:449–56.Google Scholar
  33. 33.
    Kanis JA, McCloskey EV. Epidemiology of vertebral osteoporosis. Bone 1992;13:S1–10.Google Scholar
  34. 34.
    Peck WA, Riggs BL, Bell NH, Wallace RB, Johnston CC Jr, Gordon SL, Shulman LE. Research directions in osteoporosis. Am J Med 1988;84:275–82.Google Scholar
  35. 35.
    Kanis JA, Pitt F. Epidemiology of osteoporosis. Bone 1992;31(Suppl 1):S7–15.Google Scholar
  36. 36.
    Levy E. Cost analysis of osteoporosis related to untreated menopause. Clin Rheumatol 1989;8(Suppl 2):76–82.Google Scholar
  37. 37.
    Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide projection. Osteoporosis Int 1992;2:285–9.Google Scholar
  38. 39.
    Melton LJ, O'Fallon WM, Riggs BL. Secular trends in the incidence of hip fractures. Calcif Tissue Int 1987;41:57–64.Google Scholar
  39. 39.
    Schneider EL, Guralnik JM. The aging of America: impact on health care costs. JAMA 1990;263:2335–40.Google Scholar
  40. 40.
    Naessen T, Persson I, Adami H-O, Bergstrom R, Berqvist L. Hormone replacement therapy and the risk for first hip fracture. Ann Intern Med 1990;113:95–103.Google Scholar
  41. 41.
    Rehnberg L, Nungu S, Olerud C. The incidence of femoral neck fractures in women is decreasing [Abstract]. Acta Orthop Scand 1992;63(Suppl 248):92–3.Google Scholar
  42. 42.
    Spector TD, Cooper C, Fenton Lewis A. Trends in admissions for hip fracture in England and Wales, 1968–1985. BMJ 1990;300:173–4.Google Scholar
  43. 43.
    Kanis JA, Adami S. Bone loss in the elderly. Osteoporosis Int 1994 (in press).Google Scholar
  44. 44.
    Hansen M, Overgaard K, Riis B, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991;303:961–4.Google Scholar
  45. 45.
    Falch JA, Sandvik L. Perimenopausal appendicular bone loss: a ten-year prospective study. Bone 1990;11:425–8.Google Scholar
  46. 46.
    Christiansen C, Riis BJ, Rodbro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987;1:1105–8.Google Scholar
  47. 47.
    Hui SL, Wiske PS, Norton JA, Johnston CC J. A prospective study of change in bone mass with age in postmenopausal women. J Chron Dis 1982;35:715–25.Google Scholar
  48. 48.
    Aaron JE, Makins NB, Sagreiya K. The microanatomy of trabecular bone loss in normal ageing men and women. Clin Orthop 1987;215:260–71.Google Scholar
  49. 49.
    Parfitt AM, Mathews CHE, Villaneuva AR, Kleerkoper M, Frame B, Rao DS. Relationships between surface volume and thickness of iliac trabecular bone in ageing and osteoporosis. J Clin Invest 1983;72:1396.Google Scholar
  50. 50.
    Parfitt AM. Trabecular bone architecture in the pathogenesis and prevention of fracture. Am J Med 1987;82:68–72.Google Scholar
  51. 51.
    Krolner B, Pors Nielsen S. Bone mineral content of the lumbar spine in normal and osteoporotic women: cross-sectional and longitudinal studies. Clin Sci 1982;62:329–36.Google Scholar
  52. 52.
    Firooznia H, Sloutskis D, Anderson JJ, Anthony JM, Kiel DP. Quantitative computed tomography assessment of spinal trabecular bone. II. In osteoporotic women with and without vertebral fractures. J Comput Assist Tomogr 1984;8:99–103.Google Scholar
  53. 53.
    Chevalley T, Rizzoli R, Nydegger V, Slosman D, Tkatch L, Rapin CH, Vasey H, Bonjour J-P. Preferential low bone mineral density of the femoral head in patients with a recent fracture of the proximal femur. Osteoporosis Int 1991;1:147–54.Google Scholar
  54. 54.
    Hui SL, Slemenda CW, Johnston CC. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988;81:1804–9.Google Scholar
  55. 55.
    Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK, et al. and the Study of Osteoporotic Fractures Research Group. Appendicular bone density and age predict hip fracture in women. JAMA 1990;263:665–8.Google Scholar
  56. 56.
    Wasnich RD, Ross PD, Davis JW, Vogel JM. A comparison of single and multi-site BMC measurements for assessment of spine fracture probability. J Nucl Med 1989;30:1166–71.Google Scholar
  57. 57.
    Wasnich RD, Ross PD, Davis JW, Vogel JM. Prediction of postmenopausal fracture risk with use of bone mineral measurements. Am J Obstet Gynecol 1985;153:745–51.Google Scholar
  58. 58.
    Wasnich RD, Ross PD, MacLean CJ, Davis JW, Vogel JM. The relative strengths of osteoporotic risk factors in a prospective study of postmenopausal osteoporosis. In: Christiansen C, Johansen JS, Riis BJ, editors. Osteoporosis vol. 1. 1984, Glostrup Hospital, Glostrup, Denmark, 394–5.Google Scholar
  59. 59.
    Wasnich RD, Ross PD, Vogel JM, Davis JW. Osteoporosis: critique and practicum. Honolulu, Hawaii: Banyan Press, 1989.Google Scholar
  60. 60.
    Lips P, Obrant KJ. The pathogenesis and treatment of hip fractures. Osteoporosis Int 1991;1:218–31.Google Scholar
  61. 61.
    Cooper C, Barker DJP, Morris J, Briggs RSJ. Osteoporosis, falls, and age in fracture of the proximal femur. BMJ 1987;295:13–5.Google Scholar
  62. 62.
    Cummings SR. Bone mass and bone loss in the elderly: a special case. In: Christiansen C, Riis B, editors. Fourth International Symposium on Osteoporosis. Redovre, Denmark, 1993:499–500.Google Scholar
  63. 63.
    Cameron JR, Mazess RB, Sorenson MS. Precision and accuracy of bone mineral determination by direct photon absorptiometry. Invest Radiol 1968;3:141–50.Google Scholar
  64. 64.
    Chestnut CH. Noninvasive techniques in the diagnosis of osteoporosis. Presented at the NIH Consensus Development Conference on Osteoporosis, 1984.Google Scholar
  65. 65.
    Gotfredsen A, Harsager C, Christiansen C. Total and regional bone mass in healthy and osteoporotic women. In: Yakamura S, editor. Advances in in vivo body composition studies. New York; Pleum Press 1990:101–6.Google Scholar
  66. 66.
    Hansen MA, Hassager C, Overgaard K, Marslew U, Riis BJ, Christiansen C. Dual-energy X-ray absorptiometry: a precise method of measuring bone mineral density in the lumbar spine. J Nucl Med 1990;31:1156–62.Google Scholar
  67. 67.
    Kanis JA, McCloskey EV, Eyres KS, O'Doherty DV, Aaron JE. Screening techniques in the evaluation of osteoporosis. In: Drife JO, Studd JWW, editors. HRT and osteoporosis. Berlin: Springer, 1990:135–47.Google Scholar
  68. 68.
    Kanis JA, Caulin F, Russell RGG. Problems in the design of clinical trials in osteoporosis. In: Dixon A St J, Russell RGG, Stamp TCB, editors. Osteoporosis: a multidisciplinary problem. Royal Society of Medicine International Congress Symposium Series 55, Royal Society of Medicines, London 1983:205–22.Google Scholar
  69. 69.
    Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, et al. and the Study of Osteoporotic Fractures Research Group. Bone density and hip fractures in older women: a prospective study. Lancet 1992;341:72–5.Google Scholar
  70. 70.
    Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919–23.Google Scholar
  71. 71.
    Black DJ, Cummings SR, Melton LJ III. Appendicular bone mineral and a woman's lifetime risk of hip fracture. J Bone Miner Res 1992;7:639–46.Google Scholar
  72. 72.
    Smith DM, Khairi MRA, Johnston CC. The loss of bone mineral with aging and its relationship to risk fracture. J Clin Invest 1975;56:311–8.Google Scholar
  73. 73.
    Cleghorn DB, Polley KJ, Bellon MJ, Chatterton J, Baghurst PA, Nordin BEC. Fracture rates as a function of forearm mineral density in normal postmenopausal women: retrospective and prospective data. Calcif Tissue Int 1991;49:161–3.Google Scholar
  74. 74.
    Hui SL, Slemenda CW, Johnston CC. Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 1989;111:355–61.Google Scholar
  75. 75.
    Nordin BEC, Need AG, Chatterton BE, Horowitz M, Cleghorn DB. Bone density screening for osteoporosis. Lancet 1990;336:1327–8.Google Scholar
  76. 76.
    Ross PD, Wasnich RD, Heilbrun LK, Vogel JM. Definition of a spine fracture threshold based upon prospective fracture risk. Bone 1987;8:271–8.Google Scholar
  77. 77.
    Melton LJ, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227–33.Google Scholar
  78. 78.
    Gardsell P, Johnell O, Nilsson BE. Predicting fractures in women by using forearm bone densitometry. Calcif Tissue Int 1989;44:235–42.Google Scholar
  79. 79.
    Gardsell P, Johnell O, Nilsson BE. The predictive value of bone loss for fragility fractures in women: a longitudinal study over 15 years. Calcif Tissue Int 1991;49:90–4.Google Scholar
  80. 80.
    Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking and death from coronary artery disease: overall findings and differences by age for 316099 white men. Arch Intern Med 1992;152:56–64.Google Scholar
  81. 81.
    Khaw K, Barrett-Connor E, Suarez L, Crique MH. Predictors of stroke associated mortality in the elderly. Stroke 1984;15:244–8.Google Scholar
  82. 82.
    Wilson JMG, Jungner G. Principles and practice of screening for disease. WHO Public Health Paper no. 34. Geneva: World Health Organization, 1968.Google Scholar
  83. 83.
    Kanis JA. Screening for postmenopausal osteoporosis: a review for the Department of Health, UK, 1992.Google Scholar
  84. 84.
    Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990;323:878–83.Google Scholar
  85. 85.
    Geusens P, Dequeker J, Verstraeten A, Nijs J. Age, sex and menopause related changes of vertebral and peripheral bone: population study using dual and single photon absorptiometry and radiogrammetry. J Nucl Med 1986;27:1540–9.Google Scholar
  86. 86.
    Nilas L, Gotfredsen A, Riis BJ, Christiansen C. The diagnostic validity of local and total bone mineral measurements in postmenopausal osteoporosis and osteoarthritis. Clin Endocrinol 1986;25:711–20.Google Scholar
  87. 87.
    Devogelaer JP, Depresseux G, Nagant de Deuxchaisnes C. Reproducibility of single photon absorptiometry by rectilinear forearm scanning at three sites. In: Dequeker J, Geusens P, Wahner HW, editors. Bone mineral measurement by photon absorptiometry. Leuven: Leuven University Press, 1988:215–9.Google Scholar
  88. 88.
    Kollerup G, Sorensen HA. Bone mass in the forearm by dual photon energy X-ray absorptiometry. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress, 1990:736–8.Google Scholar
  89. 89.
    Garn SM, Sullivan TV, Decker SA, Larkin FA, Hawthorne VM. Continuing bone expansion and increasing bone loss over a two-decade period in men and women from a total community sample. Am J Hum Biol 1994 (in press).Google Scholar
  90. 90.
    Hui SL, Slemenda CW, Johnston CC. The contribution of bone loss to postmenopausal osteoporosis. Osteoporosis Int 1990;1:30–4.Google Scholar
  91. 91.
    Stepan JJ, Pospichal J, Schreiber V, Kanka J, Mensik J, Presl J, Pacovsky V. The application of plasma tartrate-resistant acid phosphatase to assess changes in bone resorption in response to artificial menopause and its treatment with estrogen and norethisterone. Calcif Tissue Int 1989;45:273–80.Google Scholar
  92. 90.
    Crilly RG, Jones MM, Horsman A, Nordin BEC. Rise in plasma alkaline phosphatase at the menopause. Clin Sci 1980;58:341–2.Google Scholar
  93. 93.
    Christiansen C, Riis BJ, Nilas L, Rodbro P, Deftos L, Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis. Lancet 1985;2:800–1.Google Scholar
  94. 94.
    Stepan JJ, Pospichal J, Presl J, Pacovsky V. Bone loss and biochemical indices of bone remodelling in surgically induced postmenopausal women. Bone 1987;8:279–84.Google Scholar
  95. 95.
    Delmas PD. Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease. Endocrinol Metab Clin North Am 1990;19:1–18.Google Scholar
  96. 96.
    Johansen JS, Riis BJ, Delmas PD, Christiansen C. Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. Eur J Clin Invest 1988;18:191–5.Google Scholar
  97. 97.
    Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991;72:367–73.Google Scholar
  98. 98.
    Horsman A, Birchall MN. Assessment and modification of hip fracture risk: predictions of a stochastic model. In: DeLuca HF, Mazess R, editors. Osteoporosis: physiological basis, assessment and treatment. New York: Elsevier, 1990:45–50.Google Scholar
  99. 99.
    Trotter MN, Broman GE, Peterson RR. Densities of bones of white and negro skeletons. J Bone Joint Surg [Am] 1960;42:50–8.Google Scholar
  100. 100.
    Nordin BEC, MacGregor J, Smith DA. The incidence of osteoporosis in normal women: its relation to age and the menopause. Q J Med 1966;137:25–8.Google Scholar
  101. 101.
    Sowers MR, Wallace RD, Lemke JH. Correlates of mid-radius bone density among postmenopausal women: a community study. Am J Clin Nutr 1985;41:1045–53.Google Scholar
  102. 102.
    Evers SE, Orchard JW, Haddad RG. Bone density in postmenopausal North American Indians and Caucasian females. Hum Biol 1985;57:719–26.Google Scholar
  103. 103.
    Dequeker J, Tobing L, Rutten V, Geusens P, Medos Study Group. Relative risk factors for osteoporotic fracture: a pilot study of the MEDOS questionnaire. Clin Rheumatol 1991;10:49–53.Google Scholar
  104. 104.
    Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316:363–9.Google Scholar
  105. 105.
    Stevenson JC, Lees B, Devenport M, Cust MP, Ganger KF. Determinants of bone density in normal women: risk factors for future osteoporosis. BMJ 1989;298:924–8.Google Scholar
  106. 106.
    Laitinen K, Valimaki M, Keto P. Bone mineral density measured by dual-energy X-ray absorptiometry in healthy Finnish women. Calcif Tissue Int 1991;48:224–31.Google Scholar
  107. 107.
    Krall EA, Dawson-Hughes B. Smoking and bone loss among postmenopausal women. J Bone Miner Res 1991;6:331–8.Google Scholar
  108. 108.
    Aloia JF, Vaswani AN, Yeh JK, Ross P, Ellis K, Cohn SH. Determinants of bone mass in postmenopausal women. Arch Intern Med 1983;143:1700–4.Google Scholar
  109. 109.
    Bauer DC, Browner WS, Cauley JA, Orwoll ES, Scott JC, Black DM, et al. for the Study of Osteoporotic Fractures Research Group. Factors associated with appendicular bone mass in older women. Ann Intern Med 1993;118:657–75.Google Scholar
  110. 110.
    Cooper C, Atkinson EJ, Wahner HW, O'Fallon WM, Riggs BL, Judd HL, Melton LJ III. Is caffeine consumption a risk factor for osteoporosis? J Bone Miner Res 1992;7:465–71.Google Scholar
  111. 111.
    Elliott CA, Price VH, Wallace WA. The predictive value of radial and hip fracture for further fracture risk in Nottingham. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress, 1990:216–7.Google Scholar
  112. 112.
    Johnston CC, Melton LJ, Lindsay R, Eddy DM. Clinical indications for bone mass measurements. Report of scientific advisory committee of the National Osteoporosis Foundation. Bone Miner Res 1989;4 (Suppl 2):1–28.Google Scholar
  113. 113.
    Slemenda CW, Hui SL, Longscope C, Wellman H, Johnston CC. Predictors of bone mass in perimenopausal women: a prospective study of clinical data using photon absorptiometry. Ann Intern Med 1990;112:96–101.Google Scholar
  114. 114.
    van Hemert AM. Epidemiology of osteoporosis and prediction of fractures: a nine-year population based follow up. Thesis, Erasmus University of Rotterdam, 1989.Google Scholar
  115. 115.
    Citron JT, Ettinger B, Genant HK. Prediction of peak premeno-pausal bone mass using a scale of weighted clinical variables. In: Christiansen C, Johansen JS, Riis BJ, editors. Osteoporosis 1987, vol. 1. Denmark: Norhaven, 1987:146–9.Google Scholar
  116. 116.
    Elders PJM, Netelenbos JC, Lips P, Khoe E, van Ginkil FC, Hulshof KFAM, van der Stelt PV. Perimenopausal bone mass and risk factors. Bone Miner 1989;7:289–99.Google Scholar
  117. 117.
    Nguyen T, Sambrook P, Kelly P, Jones G, Lord S, Freund J, Eisman J. Prediction of osteoporotic fractures by postural instability and bone density. BMJ 1993;307:1111–5.Google Scholar
  118. 118.
    Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskovitz MA. Hip fracture and the use of estrogens in postmenopausal women: the Framingham Study. N Engl J Med 1987;317:1169–74.Google Scholar
  119. 119.
    Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, Mack TM. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981;95:28–31.Google Scholar
  120. 120.
    Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–37.Google Scholar
  121. 121.
    Naessen T, Parker R, Persson I, Zack M, Adami H-O. Time trends in incidence rates of first hip fracture in the Uppsala health care region, Sweden, 1965–1983. Am J Epidemiol 1989;130:289–99.Google Scholar
  122. 122.
    Daly E, Roche M, Barlow D, Gray A, McPherson K, Vessey M. Hormone replacement therapy in the menopause: an analysis of benefits, risks and costs. Report to the Department of Health, UK, 1991.Google Scholar
  123. 123.
    Lindsay R, Hart DM, MacLean A, Clark AC, Kraszewski A, Garwood J. Bone response to termination of oestrogen treatment. Lancet 1978;1:1325–7.Google Scholar
  124. 124.
    Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;1:459–61.Google Scholar
  125. 125.
    Stevenson JC, Kanis JA, Christiansen C. Bone density measurement. Lancet 1992;339:370–1.Google Scholar
  126. 126.
    Browner WS, Seeley DG, Vogt TM, Cummings SR. Non-trauma mortality in elderly women with low bone mineral density. Lancet 1991;338:355–8.Google Scholar
  127. 127.
    Johansson C. Osteoporosis in the elderly. MD thesis, University of Goteborg, 1993.Google Scholar
  128. 128.
    Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67–72.Google Scholar
  129. 129.
    Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zank MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985–90.Google Scholar
  130. 130.
    Brinton LA, Hoover R, Fraumeni JF. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986;54:825–32.Google Scholar
  131. 131.
    Bergkvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progesterone replacement therapy. Am J Epidemiol 1989;130:221–8.Google Scholar
  132. 132.
    Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861–7.Google Scholar
  133. 133.
    Cauley J, Cummings SR, Black DM, Mascioli SR, Seeley DG, Prevalence and determinants of estrogen replacement therapy in elderly women. Am Obstet Gynecol 1990;163:1438–44.Google Scholar
  134. 134.
    Egeland G, Kuller L, Matthews K, Kelsey S, Cauley J, Guzick D. Premenopausal determinants of menopausal estrogen use. Preventive Med 1991;20:343–9.Google Scholar
  135. 135.
    Vandenbroucke JP. Postmenopausal oestrogen and cardiopro-tection. Lancet 1991;337:833–4.Google Scholar
  136. 136.
    Nachtigall L, Nachtigall RH, Nachtigall RD, Beckman EM, Estrogen replacement therapy. II. A prospective study in the relationship in carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979;54:74–9.Google Scholar
  137. 137.
    Persson I, Falkeborn M, Lithell H. The effect of myocardial infarction (MI) risk of estrogens and estrogen-progestin combinations. In: Sixth international congress on the menopause. Bangkok: Parthenon Publishing Group, 1990:223.Google Scholar
  138. 138.
    Tosteson ANA, Rosenthal DI, Melton LJ, Weinstein MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990;113:594–603.Google Scholar
  139. 139.
    Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75–8.Google Scholar
  140. 140.
    Hillner BE, Hollenberg JP, Pauker SG. Postmenopausal estrogens in prevention of osteoporosis. Am J Med 1986;80:1115–27.Google Scholar
  141. 141.
    Chapuy MC, Arlot ME, Duboeuf F, Brun J, Cronzet B, Arnaud S, Delmas PD, Meunier PJ. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637–42.Google Scholar
  142. 142.
    Dawson-Hughes B. Calcium supplementation and bone loss: a review of controlled clinical trials. Am J Clin Nutr 1991;54:274S-280S.Google Scholar
  143. 143.
    Elders PJM, Netelenbos JC, Lips P, van Ginkel FC, Khoe E, Leeuwenkamp OR, Hackeng WHL, van der Stelt PF. Calcium supplementation reduces vertebral bone loss in perimenopausal women: a controlled trial in 248 women between 46 and 55 years of age. J Clin Endocrinol Metab 1991;73:533–40.Google Scholar
  144. 144.
    Kanis JA, Johnell O, Gullberg B, Allander E, Dilzen G, Gennari C, et al. Evidence for the efficacy of bone active drugs in the prevention of hip fracture. BMJ 1992;305:1124–8.Google Scholar
  145. 145.
    Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in postmenopausal osteoporosis. N Engl J Med 1990;322:1265–71.Google Scholar
  146. 146.
    Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73–9.Google Scholar
  147. 147.
    Reginster JY, Denis D, Albert A, et al. One-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987;2:1481–3.Google Scholar
  148. 148.
    Reginster JY, Lecart MP, Deroisy R, Sarlet N, Denis D, Ethgen D, Collette J, Franchimont P. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989;2:1469–71.Google Scholar
  149. 149.
    Overgaard K, Hansen MA, Nielsen V-AH, Riis BJ, Christiansen C. Discontinuous calcitonin treatment of established osteoporosis: effects of withdrawal of treatment. Am J Med 1990;89:1–6.Google Scholar
  150. 150.
    Peyron R, Serrurier D, Edouard C, Ghozlan R, Mayoux-Benhamou A, Meunier PJ. Treatment of high remodelling vertebral osteoporosis with human calcitonin: a two-year double blind placebo-controlled trial in 93 patients. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress, 1990:1430–2.Google Scholar
  151. 151.
    Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556–61.Google Scholar
  152. 152.
    Orimo H, Shiraki M, Hayashi T, Nakamura T. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with l(OH)-vitamin D3. Bone Miner 1987;3:47–52.Google Scholar
  153. 153.
    Tilyard M, Spears GFS, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357–62.Google Scholar
  154. 154.
    Felson DT, Sloutskis D, Anderson JJ, Anthony JM, Kiel DP. Thiazide diuretics and the risk of hip fracture. JAMA 1991;265:370–3.Google Scholar
  155. 155.
    LaCroix AZ, Wienpahl J, White LR, Wallace RB, Scherr PA. George LK, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 1990;322:286–90.Google Scholar
  156. 156.
    Ray WA. Long term use of thiazide diuretics and the risk of hip fracture. Lancet 1989;1:687–90.Google Scholar
  157. 157.
    Kanis JA, Beneton MNC, Gennari C, Gullberg B, Johnell O, Mazzuoli GF, Passeri M. Effects of anabolic steroids on cortical bone and fractures. In: Christiansen C, Riis B, editors. Fourth international symposium on osteoporosis. Redovra: Denmark, 1993:308–10.Google Scholar
  158. 158.
    Riggs BL, Hodgson SF, O'Fallon WM, Chao Eys, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;22:802–9.Google Scholar
  159. 159.
    Pak CY, Sakhaee K, Zerwekh JE, Parcel C, Peterson R, Johnson K. Safe and effective treatment of osteoporosis and intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures. J Clin Endocrinol Metab 1989;68:150–9.Google Scholar
  160. 160.
    Kanis JA, Meunier PJ, Should we use fluoride to treat osteoporosis? Q J Med 1984;53:145–64.Google Scholar
  161. 161.
    Mamelle N, Meunier PJ, Dusan R, Guilaume M, Martin JL, Gaucher A, et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988;2:361–5.Google Scholar
  162. 162.
    Cummings SR, Black D. Should perimenopausal women be screened for osteoporosis? Ann Intern Med 1986;104:817–23.Google Scholar
  163. 163.
    Suman VJ, Atkinson EJ, O'Fallon WM, Black DM, Melton LJ. A nomogram for predicting lifetime hip fracture risk from radius bone mineral density and age. Bone 1993;14:843–6.Google Scholar
  164. 164.
    Cuckle HS, Wald NJ. Principles of screening. In: Wald N, editor. Antenatal and neonatal screening. Oxford: Oxford University Press, 1984:1–22.Google Scholar
  165. 165.
    Cadman D, Chambers L, Feldman W, Sackett D. Assessing the effectiveness of community screening programmes. JAMA 1984;251:1580.Google Scholar

Copyright information

© European Foundation for Osteoporosis 1994

Authors and Affiliations

  • J. A. Kanis
    • 1
  • J. A. Kanis
    • 1
  1. 1.WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical BiochemistryUniversity of Sheffield Medical SchoolSheffieldUK

Personalised recommendations